Recurso de anulación con arreglo al art. 263 TFUE

pendientes ante el Tribunal Europeo contra la autorización de
Comirnaty de Pfizer/BioNTech (T-109/23) & Spikevax de Moderna (T-108/23)

Los casos presentados por DDR. Renate Holzeisen

Pedimos disculpas a nuestros espectadores por la calidad del vídeo, estamos trabajando para ofrecer una grabación de mejor calidad en breve.

Haga clic aquí para ver las diapositivas de la presentación:

Acción legal – Anulación_RH_CHDEurope.pdfDescargar

Official-Journal-of-the-EU-T-109-23Descargar

T-109-23-acción-por-anulación-Comirnaty-Pfizer-BioNTechDescargar

T-108-23-Action-for-annulment-163-TFUE-Spikevax-ModernaDescargar

Comirnaty – Anexos Holzeisen

A.1
A.2
A.3
A.4
A.5
A.6
A.7
A.8
A.9
A.10
A.12 EC Impl. of the advanced Therapies Reg. 9.7.2008
A.13 EC Impl. of the advanced Therapies Reg. 8.4.2008
A.14 mRNA vaccine toxicity Palmer et al 12.1.23
A.15 Bhakdi et al expert-statement Comirnaty children
A.16 CHD Europe F.O.I.A. 22.7.22
A.17 EMA ASK-117768 Letter to the rquester 21.9.22
A.18 EMA Assessment Report 853699 2022
A.19 WHO guideline nonclinical evaluation vaccines 2005
A.20 EMA Guid. precli.l clin. gen transfer products 4.4.01
A.21 EMA Withdrawel Note for guidance testing vaccines 21.7.16
A.22 EMA Guidance testing vaccines 17.12.97
A.23 WHO Guidlines DNA vaccines 2007
A.24 EMA Concept paper DNA vaccines 15.3.22
A.25 EMA Assessment Report 19.2.21
A.26 EMA Assessment Report 596333 21 Com.
A.27 WHO Covid-19 vaccine trial 29.11.21
A.28 NIH Placebos in Clinical Trials
A.29 Eudravigilance Comirnaty
A.30 Prof.U.Kämmerer Gutachten RT-PCR EN
A.31 J.Ionnidies et al. fatality rate Covid-19

Spikevax -Anexos Holzeisen

A.1
A.2
A.3
A.4
A.5
A.6
A.7
A.8
A.9
A.10
A.11
A.12
A.14 EC Impl. of the advanced Therapies Reg. 9.7.2008
A.15 EC Impl. of the advanced Therapies Reg. 8.4.2008
A.16 mRNA vaccine toxicity Palmer et al 12.1.23
A.17 Expert Stat. Moderna Vaccine, Palmer M. 30.9.21
A.18 CHD Europe F.O.I.A. 22.7.22
A.19 EMA ASK-117768 Letter to the rquester 21.9.22
A.20 Assessment Report EMA 850007 2022
A.21 WHO guideline nonclinical evaluation vaccines 2005
A.22 EMA Guid. precli.l clin. gen transfer products 4.4.01
A.23 EMA Withdrawel Note for guidance testing vaccines 21.7.16
A.24 EMA Guidance testing vaccines 17.12.97
A.25 WHO Guidlines DNA vaccines 2007
A.26 EMA Concept paper DNA vaccines 15.3.22
A.27 EMA Assessment Report Spikevax 21.2.22
A.28 Moderna clinical updates 13.4.21
A.29 WHO Covid-19 vaccine trial 29.11.21
A.30 NIH Placebos in Clinical Trials
A.31 Eudravigilance, Spikevax
A.32 Prof.U.Kämmerer Gutachten RT-PCR EN
A.33 J.Ionnidies et al. fatality rate Covid-19

Ver otros vídeos relacionados con el caso: